HCP & Bioprocessing Reagent Development



Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate the presence of residual contamination during the bioprocessing process and final biopharmaceutical product, development of custom polyclonal antibody reagents with maximum coverage against contaminant HCP extracts is required.

Rockland provides multiple customizable options for HCP antibody development. These options allow flexibility for development of early stage 
through late stage HCP detection reagents.